214 related articles for article (PubMed ID: 26441041)
21. Is neoadjuvant chemotherapy mandatory for limited-disease small-cell lung cancer?
Xu YJ; Zheng H; Gao W; Jiang GN; Xie HK; Chen C; Fei K
Interact Cardiovasc Thorac Surg; 2014 Dec; 19(6):887-93. PubMed ID: 25156899
[TBL] [Abstract][Full Text] [Related]
22. Prognostic factors affecting the risk of thoracic progression in extensive-stage small cell lung cancer.
Fukui T; Itabashi M; Ishihara M; Hiyoshi Y; Kasajima M; Igawa S; Sasaki J; Masuda N
BMC Cancer; 2016 Mar; 16():197. PubMed ID: 26955807
[TBL] [Abstract][Full Text] [Related]
23. Use and impact of adjuvant chemotherapy in patients with resected non-small cell lung cancer.
Williams CD; Gajra A; Ganti AK; Kelley MJ
Cancer; 2014 Jul; 120(13):1939-47. PubMed ID: 24668613
[TBL] [Abstract][Full Text] [Related]
24. Clinical predictors of survival in young patients with small cell lung cancer: Results from the California Cancer Registry.
Lara JD; Brunson A; Riess JW; Kelly K; Lara PN; Gandara DR
Lung Cancer; 2017 Oct; 112():165-168. PubMed ID: 29191590
[TBL] [Abstract][Full Text] [Related]
25. Treatment disparities for disabled medicare beneficiaries with stage I non-small cell lung cancer.
Iezzoni LI; Ngo LH; Li D; Roetzheim RG; Drews RE; McCarthy EP
Arch Phys Med Rehabil; 2008 Apr; 89(4):595-601. PubMed ID: 18373987
[TBL] [Abstract][Full Text] [Related]
26. Survival outcomes with the use of surgery in limited-stage small cell lung cancer: should its role be re-evaluated?
Schreiber D; Rineer J; Weedon J; Vongtama D; Wortham A; Kim A; Han P; Choi K; Rotman M
Cancer; 2010 Mar; 116(5):1350-7. PubMed ID: 20082453
[TBL] [Abstract][Full Text] [Related]
27. Association of GWAS-identified lung cancer susceptibility loci with survival length in patients with small-cell lung cancer treated with platinum-based chemotherapy.
Li D; Wei L; Xu B; Yu D; Chang J; Yuan P; Du Z; Tan W; Shen H; Wu T; Wu C; Lin D
PLoS One; 2014; 9(11):e113574. PubMed ID: 25415319
[TBL] [Abstract][Full Text] [Related]
28. Phase II trial of amrubicin and carboplatin in patients with sensitive or refractory relapsed small-cell lung cancer.
Hirose T; Nakashima M; Shirai T; Kusumoto S; Sugiyama T; Yamaoka T; Okuda K; Ohnishi T; Ohmori T; Adachi M
Lung Cancer; 2011 Sep; 73(3):345-50. PubMed ID: 21277039
[TBL] [Abstract][Full Text] [Related]
29. Population-based Results of Chemoradiotherapy for Limited Stage Small Cell Lung Cancer in The Netherlands.
Damhuis R; Widder J; Senan S
Clin Oncol (R Coll Radiol); 2018 Jan; 30(1):17-22. PubMed ID: 29102167
[TBL] [Abstract][Full Text] [Related]
30. Surveillance epidemiology and end results evaluation of the role of surgery for stage I small cell lung cancer.
Yu JB; Decker RH; Detterbeck FC; Wilson LD
J Thorac Oncol; 2010 Feb; 5(2):215-9. PubMed ID: 20101146
[TBL] [Abstract][Full Text] [Related]
31. Randomized phase II study of carboplatin and etoposide with or without obatoclax mesylate in extensive-stage small cell lung cancer.
Langer CJ; Albert I; Ross HJ; Kovacs P; Blakely LJ; Pajkos G; Somfay A; Zatloukal P; Kazarnowicz A; Moezi MM; Schreeder MT; Schnyder J; Ao-Baslock A; Pathak AK; Berger MS;
Lung Cancer; 2014 Sep; 85(3):420-8. PubMed ID: 24997137
[TBL] [Abstract][Full Text] [Related]
32. Lobectomy leads to optimal survival in early-stage small cell lung cancer: a retrospective analysis.
Varlotto JM; Recht A; Flickinger JC; Medford-Davis LN; Dyer AM; DeCamp MM
J Thorac Cardiovasc Surg; 2011 Sep; 142(3):538-46. PubMed ID: 21684554
[TBL] [Abstract][Full Text] [Related]
33. The prognostic factors in the elderly patients with small cell lung cancer: a retrospective analysis from a single cancer institute.
Liu S; Guo H; Kong L; Li H; Zhang Y; Zhu H; Yu J
Int J Clin Exp Pathol; 2015; 8(9):11033-41. PubMed ID: 26617821
[TBL] [Abstract][Full Text] [Related]
34. Chemotherapy use, outcomes, and costs for older persons with advanced non-small-cell lung cancer: evidence from surveillance, epidemiology and end results-Medicare.
Ramsey SD; Howlader N; Etzioni RD; Donato B
J Clin Oncol; 2004 Dec; 22(24):4971-8. PubMed ID: 15611512
[TBL] [Abstract][Full Text] [Related]
35. The applicability of the proposed IASLC staging revisions to small cell lung cancer (SCLC) with comparison to the current UICC 6th TNM Edition.
Ignatius Ou SH; Zell JA
J Thorac Oncol; 2009 Mar; 4(3):300-10. PubMed ID: 19156001
[TBL] [Abstract][Full Text] [Related]
36. Association of Race, Socioeconomic Factors, and Treatment Characteristics With Overall Survival in Patients With Limited-Stage Small Cell Lung Cancer.
Zhou K; Shi H; Chen R; Cochuyt JJ; Hodge DO; Manochakian R; Zhao Y; Ailawadhi S; Lou Y
JAMA Netw Open; 2021 Jan; 4(1):e2032276. PubMed ID: 33433596
[TBL] [Abstract][Full Text] [Related]
37. [Therapeutic effects and prognostic factors for the limited-stage small cell lung cancer treated with multidisciplinary therapy].
Dong XJ; Wang MZ; Zhong W; Zhang L; Zhang XT; Zhao J; Xia Y; Li LY
Zhonghua Zhong Liu Za Zhi; 2012 Mar; 34(3):216-21. PubMed ID: 22780978
[TBL] [Abstract][Full Text] [Related]
38. Third-line chemotherapy in small-cell lung cancer: an international analysis.
Simos D; Sajjady G; Sergi M; Liew MS; Califano R; Ho C; Leighl N; White S; Summers Y; Petrcich W; Wheatley-Price P
Clin Lung Cancer; 2014 Mar; 15(2):110-8. PubMed ID: 24365050
[TBL] [Abstract][Full Text] [Related]
39. Twenty-five years of clinical research for patients with limited-stage small cell lung carcinoma in North America.
Jänne PA; Freidlin B; Saxman S; Johnson DH; Livingston RB; Shepherd FA; Johnson BE
Cancer; 2002 Oct; 95(7):1528-38. PubMed ID: 12237922
[TBL] [Abstract][Full Text] [Related]
40. Small-cell lung cancer in England: trends in survival and chemotherapy using the National Lung Cancer Audit.
Khakwani A; Rich AL; Tata LJ; Powell HA; Stanley RA; Baldwin DR; Hubbard RB
PLoS One; 2014; 9(2):e89426. PubMed ID: 24586771
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
